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ABSTRACT
EVALUATION OF LIVER TRANSPLANT PRIORITIZATION METHODS
FOR HEPATOCELLULAR CARCINOMA PATIENTS
USING MULTISTATE MODELS
Sarah K. Alver
November 18, 2015
The Model for End Stage Liver Disease (MELD), used for prioritizing liver
transplantation, predicts mortality from liver disease. Patients with hepatocellular
carcinoma (HCC) risk disease progression not reflected in their MELD score.
Exception scores prioritize HCC patients higher than their MELD scores, but
advantage them over non-HCC patients. To address this, a delay of six months
for using exception scores has been implemented, and alternative HCC-specific
scores have been developed. Using multistate models, this study projects
waitlist dropout and transplant probabilities under the delay and under two
alternative scores. The delay improves equity between HCC and non-HCC
patients for the first six months waitlist time, but still advantages HCC patients
after six months. Both alternative scores would improve this inequity but increase
dropout for some HCC risk groups and decrease HCC transplant probabilities
below non-HCC probabilities. Further calibration of these scores is
recommended prior to considering them for implementation.
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CHAPTER 1
INTRODUCTION
The Model for End-Stage Liver Disease (MELD) score, which predicts
three-month mortality from liver disease, has been used to allocate liver
transplants to patients with the most need or urgency for transplant under
policies of the Organ Procurement and Transplantation Network (OPTN). The
organ transplant system is managed in the Unites States through these policies
by the United Network for Organ Sharing (UNOS) under contract with the federal
government. The MELD score was originally used to predict three-month
mortality for patients receiving TIPS (Transjugular Intrahepatic Portosystemic
Shunt) procedures1, and subsequently generalized to predict three-month
mortality risk in patients with end-stage liver disease2.
The MELD score is based on the biochemical values of bilirubin,
international normalized ratio (INR) and creatinine. It is defined by:
0.957*ln(creatinine) + 0.378*ln(bilirubin) + 1.12*ln(INR) + 0.643
where creatinine and bilirubin are in milligrams per deciliter (mg/dL). The result
of this calculation is rounded to the tenth decimal place and then multiplied by 10.
The minimum of this score is 6, and the maximum is 40. Laboratory values less
than 1 are set to 1 for the calculation, and creatinine is set to 4 for candidates
with creatinine greater than 4 or those who received two or more dialysis
treatments or 24 hours of continuous veno-venous hemodialysis within the prior
week3.
1

Liver transplant has been shown to be an appropriate treatment for
patients with hepatocellular carcinoma whose tumor characteristics meet certain
criteria for size and number. These criteria, a single tumor 5 cm or less in
diameter or up to 3 tumors 3 cm or less in diameter, have been referred to as the
Milan criteria4. Patients with hepatocellular carcinoma (HCC) often have higher
mortality risk than their calculated MELD scores would indicate due to tumor
progression rather than liver disease5, and also risk of dropout from the waiting
list due to HCC progression beyond criteria. In attempt to account for this, HCC
patients have been allocated exception MELD scores per OPTN policies which
are generally greater than their calculated MELD score. However, risk of tumor
progression beyond the Milan criteria within three months was later found to be
overestimated by these exception points 6, such that HCC patients have had
higher transplant rates and lower waitlist dropout rates than non-HCC
candidates. Thus, policies have been revised several times – for example,
candidates with single tumors less than 2 cm in size were originally granted
exception points but currently are not. Under recent policy, candidates with HCC
who met criteria according to OPTN policies received an initial exception MELD
score equivalent to a 15 percent risk of 3-month mortality7. Criteria in the OPTN
policies include stage T2 lesions, which may be one lesion greater than or equal
to 2 cm and less than or equal to 5 cm in size, or two or three lesions greater
than or equal to 1 cm and less than or equal to 3 cm in size. Additional exception
points equivalent to a 10% increase in mortality risk were given every three
months thereafter, until the patient received a transplant or became unsuitable
for transplant based on their HCC progression 7.
2

Under this system, despite previous modifications, patients with HCC
continued to have an advantage for access to transplantation when compared to
patients without HCC 5,8. Because previous policies provided advantages to
HCC patients compared to non-HCC patients, with increased transplant rates
and lower dropout rates9, OPTN/UNOS recently implemented a six-month delay
before granting exception points3. Simulation modeling previously suggested
that this delay would help decrease disparity between HCC and non-HCC
candidates 10. With the six-month delay, HCC patients will be listed at their
laboratory MELD score until the second three month extension. At that time they
will receive an exception MELD score equivalent to a 35% risk of 3-month
mortality (score of 28) and then continue with the scheduled exception point
progression every three months until they receive transplantation or become
unsuitable based on HCC progression. The exception point progression will be
capped at 34 points 3.
In addition to the six-month delay, investigators have proposed alternative
scoring models for HCC patients in attempt to address the disparity in access to
transplantation between HCC and non-HCC patients 6,11-15. These scores were
intended to more accurately reflect dropout risk for HCC patients based on HCC
and patient characteristics in addition to the laboratory MELD. Several of these
scores were summarized in a previous publication 16 and those models as well as
another model15 that was developed more recently will be briefly described here.
Review of Equivalent MELD Scores
One of the alternative HCC transplant prioritization scores, developed by
Freeman et al, estimates 90-day dropout probability for HCC patients using an
3

equation based on calculated MELD score at listing, maximum tumor size, and
alpha-fetoprotein (AFP) 6, a laboratory test used by clinicians in screening for and
monitoring HCC17. The dropout probability from the equation can then be
matched to the non-HCC MELD score with that same dropout probability. They
developed this equation by examining multiple covariates using Cox regression
models with the endpoint of time to dropout. Their data included 11431 patients,
2052 of whom received exceptions due to HCC, on the waiting list between
4/30/2003 and 12/31/04. They found that MELD at listing, maximum tumor size,
AFP and age at listing were associated with an increased relative risk of waitlist
removal (dropout), while ablation, diagnostic imaging modality (magnetic
resonance imaging or ultrasound vs computerized tomography), number of
tumors, race, gender and blood type did not have significant relative risks for
removal. They purposefully used only nondiscriminatory variables in the
equation, so age was excluded. They assessed the accuracy of their equation
with newer waiting list data from 1/1/2005 to 4/20/2005 that included 624 HCC
candidates and found that the concordance of their model was 0.781 (95% CI
0.688, 0.853). However, MELD alone was equally predictive of dropout with
concordance of 0.796 (95% CI 0.657, 0.897). Additionally, this model was
validated in a separate study in 2008 on 390 HCC transplant candidates who
received locoregional therapy. This study found concordance of 0.81 (0.685,
0935) at three months and 0.8 (0.732, 0.868) at six months for this model’s
accuracy in predicting tumor progression. For this group of patients, the model
was more predictive than MELD alone, which had concordance of 0.574 (0.420,
0.728) at three months and 0.538 (0.413, 0.663) at six months 18. The authors of
4

the validation study noted that the patients undergoing locoregional therapy had
low baseline MELD scores that could be a reason for the contrast with the
original study, which found that MELD was equally predictive of dropout.
Advantages of this score include that it was externally validated and it also
identified risk factors for HCC waitlist dropout. Disadvantages are that it
estimates dropout probability rather than an actual score, so may be difficult to
implement in practice. Also, although it was validated, it was not found to be
better than MELD alone in predicting dropout when validated on a larger, broader
group of patients.
Another score that has been developed is that by Piscaglia et al. This
score adds points to the lab MELD for waitlist time in months and a “stage score”
that incorporates tumor size and consideration for downstaging11. The stage
score included 5 points for a single nodule up to 3 cm in size, 8 points for larger
tumors or multifocal tumors within the Milan criteria, or 12 points for downstaging
protocol. The authors stated that the number of points chosen were arbitrary, but
did increase with increasing disease stage to reflect higher risk of dropout. The
downstaging protocol in this study allowed patients with HCC previously beyond
Milan criteria who underwent surgery or locoregional treatment to be listed for
transplant if the tumor size was reduced to within Milan criteria and their AFP
level did not exceed 400 nanograms per milliliter (ng/mL) during listing. During
the time of the study, the Bologna Transplantation Center in Italy adopted a
MELD-based prioritization policy (UNOS also began using the MELD in 2002
along with exception points for HCC patients), but used its own allocation policy,
which was the score described above, for patients with HCC. The patients in the
5

study included 301 HCC and non-HCC patients listed for transplant at the
Bologna Transplantation Center from 3/1/2001 to 2/28/2004, including 163
patients listed before the policy implementation and 138 listed after. They
compared dropout and transplant rates between HCC and non-HCC patients
before implementing this policy and after it had been in place for one year. They
did not find a difference in dropout between the two time periods, but HCC
patients had a significantly higher cumulative probability of transplant, assessed
using Kaplan-Meier curves, compared to non-HCC patients after implementing
the new score. This transplant probability was also significantly higher compared
to HCC probabilities before implementing their new score, and they did not find
this difference for non-HCC patients. There was concern that the transplant
rates for HCC were excessively greater than those for non-HCC patients when
the policy was first implemented. However, the authors stated that when their
policy was first implemented many HCC patients initially received priority due to
their long waiting time, but after these initial patients underwent transplantation
the rates became more equal between HCC and non-HCC patients. They also
pointed out that non-HCC dropout rates did not significantly increase; however,
the proportion of non-HCC patients still waiting for transplant at the end of the
study period did increase. Based on this, the policy at that center was updated to
provide fewer points: 3 points for a single tumor up to 3 cm with 0.5 points per
month waiting time and 6 points for larger tumors, multiple tumors or
downstaging protocol with 1 point per month waiting time. Results of this
updated score were not included in the study. Advantages of this score include
that it does consider HCC characteristics in addition to MELD. Another
6

advantage, in theory, is that it was updated based on results, reflecting the idea
that patient and center characteristics can change over time, though results of
the update are not known. Other authors have stated that allocating increased
points for downstaging is controversial as these patients may have decreased
dropout risk16; also a waiting period before transplant may be recommended19.
While downstaging protocols are used in some regions in the United States19,20,
automatic exception points for downstaged tumors are generally not given3,20, so
implementing a score that gives increased points for downstaging in the US may
be difficult.
Another equivalent MELD score, developed by Vitale et al14, was derived
using transplant benefit rather than dropout risk as an endpoint to equate with
that of non-HCC patients. This is in contrast to several of the other scores
reviewed here which equate to non-HCC using dropout risk. It also includes a
separate utility score intended to avoid poor post-transplant outcomes. The
authors state that using 3-month dropout risk as an endpoint for both HCC and
non-HCC patients may be problematic because dropout for non-HCC patients is
usually due to death, whereas dropout for HCC patients is usually due to tumor
progression. To derive their score, the investigators studied covariates using
competing risk models for analyzing waitlist outcomes, to allow for the outcomes
of transplant, death or still waiting, and Cox proportional hazard regression
models for analyzing transplant outcomes. They studied 2697 patients who were
placed on the transplant waiting list and 1702 who were undergoing liver
transplant during 2004-2009 in the North Italy Transplant Program area. The final
covariates used in the score were laboratory MELD and AFP. The paper notes
7

that AFP was associated with death on the waitlist for HCC patients, but had a
more significant impact on post-transplant survival. Monthly death probabilities
were obtained from the competing risk and Cox models, and then used to
simulate 1000 outcomes (life expectancy in months based on the covariates) for
both HCC and non-HCC groups. Then a regression model was used to estimate
the five-year transplant benefit based on MELD for non-HCC patients and MELD
and AFP for HCC patients, and these were equated between the two groups to
obtain an equivalent MELD score. Thus, the HCC transplant survival benefit for
a given equivalent MELD score would be equal to that of non-HCC patients with
the same numerical value for MELD. They also developed a utility score that,
expressed as a linear relationship between log 10 AFP and MELD, calculates the
maximum MELD a patient may have with any given AFP value (or vice versa) to
prevent unacceptable post-transplant outcomes, which were defined as less than
50% survival at five years. Another difference between this score and others
reviewed here is that the term for AFP is negative (so a patient will receive fewer
points for a higher AFP), which follows from their findings that AFP had a more
significant impact on post-transplant survival and their use of survival benefit as
the point to equate with non-HCC MELD scores. An advantage of this score is
that it does consider both dropout and post-transplant survival. A disadvantage
may be that AFP is the only HCC-specific characteristic included in the model,
where other investigators have found that additional HCC-related characteristics
such as tumor size can influence dropout risk5,6. The authors state that the score
needs external validation and further refinement.

8

Toso et al developed an HCC scoring model called the dropout equivalent
MELD in 2012 that included age, laboratory MELD, tumor size, ln(AFP), number
of tumors, diagnosis (additional causes of liver disease including alcohol,
hepatitis C virus, hepatitis B virus, hemochromatosis, non-alcoholic
steatohepatitis and “other”) in the prediction of three-month dropout probability12.
The coefficients were positive for all the HCC-related covariates in the score as
well as for age. In deriving this model, the investigators used OPTN data from
January 2004 to December 2009 including 5498 HCC patients and 43528 nonHCC patients. They restricted age to ≥45 years. Other variables explored
included total tumor volume. They used multistate modeling, competing risks
analysis and linear regression to identify covariates associated with three-month
dropout probability and to model that probability as a function of them. They
derived an equation estimating a logit transformation of dropout probability as a
function of the covariates for each group, HCC and non-HCC, and then set the
HCC and non-HCC equations equal to each other to obtain the dropout
equivalent MELD. The paper notes that all patients with HCC are given the
same number of exception points at each time point under the current policy.
Though most are given a higher score than their dropout probability warrants,
some HCC patients would be underserved by receiving a lower score than their
dropout probability would indicate based on their HCC characteristics.
Advantages of this score include that it incorporates several HCC-related
covariates, which were previously established as risk factors for dropout, and is
on the same scale as the laboratory MELD. Disadvantages include the potential
ethical concern of including age in the model as well as possible worse post9

transplant outcomes for older patients, and also the potential of higher scoring of
patients with aggressive tumors who may have higher risk of HCC recurrence
post-transplant. The paper notes that prospective assessment and external
validation of the model could address this along with a minimum 3-month wait
before transplantation if needed, to exclude those with high risk of post-transplant
recurrence. The authors also noted the need for ongoing assessment and
updating of such a model; for example, adjustment for newly identified risk
factors for dropout or changes in other HCC treatments.
In 2014, Toso et al developed a new equivalent MELD score that uses
laboratory MELD, number of tumors, AFP, and tumor size 13. This model was
developed using a training set of 49026 patients from the United States, listed
between 1/1/2004 and 12/31/2009, and validated on two datasets, one with
20475 United States patients (listed 1/1/2009 to 12/31/2011) and the other with
1781 United Kingdom patients (listed 7/1/2008 to 9/30/2011). The coefficients for
all the covariates in this equivalent score are positive. The score uses discrete
cutoff points, noted by the authors to be clinically relevant, for all the covariates
except laboratory MELD. This is discussed further in Chapter 3. In contrast,
their previous score used continuous values for most covariates. For this model,
the investigators decided not to use age and type of liver disease since these
factors are not used when prioritizing non-HCC patients. Similarly to the model
they developed in 2012 described earlier, this model was based on three-month
dropout probability, which was modeled using the covariates listed above and
then equated to the three-month dropout probability of non-HCC patients to
obtain an equivalent HCC MELD score. They termed this score the “new dropout
10

equivalent MELD (deMELD)”. Using the validation data sets, they validated the
resulting score as well as the exception MELD score, laboratory MELD, and a
variation of their score which takes the maximum of the calculated new deMELD
and the laboratory MELD (termed “mixed new deMELD”). The concordance
indices for the mixed new deMELD were 0.67 (95%CI 0.622, 0.714) in the US
validation set and 0.652 (95%CI 0.553, 0.745) in the UK validation set, compared
to 0.566(0.532, 0.597) and 0.527(0.483, 0.594) respectively for the exception
MELD and 0.663(0.616, 0.707), 0.657(0.56, 0.75) respectively for the laboratory
MELD. The authors recommended that the score be updated at least every 3
months during listing, and this would capture improvements due to other
therapies such as ablation (e.g. a smaller tumor size after treatment would result
in a lower deMELD score). Again, they noted that the score could lead to
transplantation of patients with more aggressive HCC that risk post-transplant
recurrence, and suggested considering a 3-6 month waiting time to help control
this risk. They also discussed the potential of building a model based on
transplant benefit rather than or in addition to dropout risk.
The MELD EQ , derived by Marvin et al in 201515, includes laboratory
MELD, ln(AFP), number of tumors, maximum tumor size, and a constant that is
increased after six months on the waiting list. The authors derived this score
using OPTN data from 1/22/2005 to 9/30/2009, including 7289 HCC patients and
34310 non-HCC patients. They examined previously established covariates
using Cox regression including laboratory MELD, ln(AFP), number of tumors, and
tumor size; all were significant predictors of dropout. The authors then equated
the dropout hazard based on these covariates to that of non-HCC patients based
11

on MELD alone to derive an equivalent MELD score. An approximation of the
difference in log baseline hazard rates for dropout between HCC patients and
non-HCC was made to determine a constant for less than 6 months after listing
and another for waitlist time of 6 months or greater. Also, if the laboratory MELD
was greater than the calculated MELD EQ , the MELD EQ was taken to be the
laboratory MELD. In addition, projections were made using multistate modeling
to determine what transplant and dropout probabilities would be for HCC patients
if the MELD EQ were implemented. This projection method is the same as that
described in the study in Chapter 3 of this thesis, and is discussed there in detail.
The authors of the original MELD EQ study found a concordance index of 0.741
for waitlist dropout. Advantages to the MELD EQ include that it uses HCC
characteristics as well as laboratory MELD and is on the same scale as the
laboratory MELD. Also, projections for its use, stratified by ranges of the MELD
and MELD EQ scores, were made in its original publication. With these
projections, the authors noted good alignment with the non-HCC groups in
projected transplant probabilities, such that HCC patients and non-HCC patients
with similar dropout risk based on MELD EQ and MELD strata also had similar
projected transplant probabilities. A disadvantage, based on their projections, is
that HCC projected dropout probabilities did not match the corresponding actual
non-HCC probabilities as well as ideal for most strata; they were projected to
decrease below non-HCC probabilities for higher risk strata. The investigators
also noted that patients at higher risk for dropout as determined by their higher
MELD EQ score also had worse post-transplant survival, so a potential problem
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with this score could be increased transplantation in patients who may have
poorer outcomes.
In summary, all of the proposed scores reviewed here have potential to
improve equity between transplant and dropout probabilities between HCC and
non-HCC patients, since they take HCC characteristics into account, and several
of them took calculated HCC dropout risk into account. In contrast, the
scheduled exception point progression that has been in place, and will still be in
place after six months on the waiting list, assigns the same priority scores to all
HCC patients regardless of their actual risk of dropout. Of the equivalent scores
described here, the MELD EQ and mixed new deMELD were derived most
similarly, use similar covariates, and both are on the same scale as the MELD
itself.
The primary aims of this thesis were to project outcomes for both HCC
and non-HCC patients under the recently implemented six-month delay
compared with under the MELD EQ , as well as evaluate alternative MELD scores
for use by HCC patients. Evaluation of the six-month delay compared to the
MELD EQ will be discussed in Chapter 2. Since the MELD EQ and the mixed new
deMELD are the most similar as described above, they were selected for
comparison with each other in terms of projected transplant and dropout
probabilities. This comparison will be presented in Chapter 3. Concluding
remarks and future research are given in Chapter 4.
Per the University of Louisville Human Subjects Protection Program
Guide-006, the OPTN data used here are considered public and do not meet the
definition of “human subject”, so IRB review and approval was not needed. The
13

data reported here have been supplied by UNOS as the contractor for OPTN.
The interpretation and reporting of these data are the responsibility of the
author(s) and in no way should be seen as an official policy of or interpretation by
the OPTN or the US Government.
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CHAPTER 2
SIX-MONTH DELAY AND MELD EQ COMPARISON
As discussed in Chapter 1, under recent OPTN policies where exception
points were given at listing and then progressed every three months for liver
transplant candidates with HCC, patients with these exceptions have had higher
transplant rates and lower dropout rates compared to patients without HCC 5,8.
To address this, a delay of six months before granting exception points to HCC
patients has recently been implemented. A secondary aim of this delay was to
avoid transplanting HCC patients with aggressive tumors who may have a high
recurrence risk post-transplant. Under the delay, candidates will be listed at their
laboratory MELD scores until the second three month extension, at which time
they will be assigned 28 points and continue with the scheduled progression of
exception points. These exception points will be capped at 34 3.
Other methods for addressing this disparity between HCC and non-HCC
patients have been proposed, including equivalent MELD scores for HCC
patients 6,11-15. These scores were meant to reflect mortality risk for HCC patients
more accurately than scheduled progression of exception points. These are
described in Chapter 1, including the MELD EQ , which again was derived by
determining dropout hazard rates based on established HCC characteristics as
well as laboratory MELD and then equating this hazard to that of non-HCC
patients to find the corresponding equivalent MELD score. Incidentally, as noted
15

in Chapter 1, the MELD EQ also included a waitlist time factor derived as part of
the scoring system which increased an HCC patient’s score after 6 months on
the waiting list15. As it is on the same scale as the laboratory MELD score for
non-HCC patients, it could be used comparably.
The main objective of this study was to compare the projected effect of the
six-month delay to prioritization using MELD EQ scores on HCC and non-HCC
dropout and transplant probabilities. These projections for HCC patients were
studied for the MELD EQ in its original publication15, and projections for transplant
rates and mortality under the delay were previously studied by Heimbach et al
using simulation methods10. However, the current study compares outcomes
under both approaches and utilizes more recent UNOS data. Further, while the
previous MELD EQ study only evaluated projected effects on HCC patients, the
current study includes projections for non-HCC patients as well. And though the
earlier study by Heimbach et al demonstrated improved equity between HCC and
non-HCC patients using the six-month delay, the effects of the delay on patients
in various dropout strata were not specifically examined. Using UNOS data and
multistate modeling, projected waitlist dropout and transplant probabilities were
evaluated for both HCC and non-HCC patients in varying risk strata under the
six-month delay and the MELD EQ scoring system.

METHODS
Data
Data were obtained on all patients who were added to the UNOS liver
transplant waitlist on or after 10/01/2009, based on OPTN data as of 06/30/14,
16

and who were at least 18 years old at time of initial listing. Patients with
exceptions other than HCC were excluded, and the non-HCC dataset restricted
to patients with no exceptions. Patients listed as status 1A or 1B and HCC
patients who were missing HCC-related covariate data were also excluded.

Outcomes and Covariates
The main outcomes studied included actual and projected dropout and
transplant probabilities for HCC and non-HCC patients based on the recent
practice of scheduled progression of exception points, the six-month delay, and
prioritization using MELD EQ scores. The covariates used in the MELD EQ model
were the natural log of AFP (ln(AFP)), laboratory MELD, maximum tumor size,
and number of tumors. Dropout was defined as removal from the waiting list due
to death, determined medically unsuitable, or too sick for transplant. Transplant
was defined as having received transplant for any reason. Those who remained
on the waiting list or were removed due to improvement were considered
censored.
Statistical Methods
The MELD EQ was calculated for all HCC patients at each follow-up time
using the following equation:
MELD EQ =

max(lab MELD, 1.143*MELD + 1.324*ln(AFP)
+ 1.438*Number of Tumors + 1.194*Max Tumor Size + c(t) ),
where c(t) = -2/0.146 for t<6 months
and c(t)= -1/0.146 for t≥6 months

17

Observations were categorized into ranges based on their MELD EQ and
lab MELD scores. These ranges included <12, 12-15, 16-21, 22-27, and 28-40.
Scores of 22 and above were categorized based on the previous exception
points granted at three-month intervals and then combined due to sparse data in
the higher risk groups.
These categories were used as the transient states in a nonparametric
multistate model for dropout and transplant probabilities, using the R package
msSurv 21. Figure 1 displays a schematic diagram of the multistate model used
for this portion of the study. In a multistate model, patients can transition
between the transient states at any time but cannot transition out of the terminal
states. Briefly, our multistate model consists of five transient states (the MELD /
MELD EQ risk categories, labeled states 1-5) and two terminal states of waitlist
dropout (state 6) and transplantation (state 7). Let the number of patients in
state 𝑖𝑖 at time t be 𝑌𝑌𝑖𝑖 (𝑡𝑡). These individuals are the number ‘at risk’ of making a

transition out of state 𝑖𝑖 at that time. The number of individuals making a

transition from state 𝑖𝑖 to state 𝑗𝑗 at time t is denoted 𝑑𝑑𝑁𝑁𝑖𝑖𝑖𝑖 (𝑡𝑡). Then, the non-

parametric estimate of the transition hazard from state 𝑖𝑖 to state 𝑗𝑗 at time t is

𝑑𝑑𝐴𝐴̂𝑖𝑖𝑖𝑖 (𝑡𝑡) = 𝑑𝑑𝑁𝑁𝑖𝑖𝑖𝑖 (𝑡𝑡)⁄𝑌𝑌𝑖𝑖 (𝑡𝑡). These rates give the instantaneous risk of transition

from state 𝑖𝑖 to state 𝑗𝑗 at that time. These transition hazards are combined into

� (𝑡𝑡) (a 7 x 7 matrix in this case), with the offthe state transition intensity matrix 𝑑𝑑A

diagonal elements given by the 𝑑𝑑𝐴𝐴̂𝑖𝑖𝑖𝑖 (𝑡𝑡) terms and the diagonal elements equal to
𝑑𝑑𝐴𝐴̂𝑖𝑖𝑖𝑖 (𝑡𝑡) = − ∑𝑗𝑗≠𝑖𝑖 𝑑𝑑𝐴𝐴̂𝑖𝑖𝑖𝑖 (𝑡𝑡). The state transition intensity matrices are then used to

estimate the state transition probability matrix P(𝑠𝑠, 𝑡𝑡), where each element in the
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matrix 𝑃𝑃𝑖𝑖𝑖𝑖 (𝑠𝑠, 𝑡𝑡) gives the probability of making a transition starting from state 𝑖𝑖 at
time 𝑠𝑠 to state 𝑗𝑗 at time t. The elements of P(𝑠𝑠, 𝑡𝑡) are estimated by the Aalen-

� (𝑠𝑠, 𝑡𝑡) = ∏𝑢𝑢 ∈(𝑠𝑠,𝑡𝑡]�I + 𝑑𝑑A
� (𝑢𝑢)�, where 𝑢𝑢 indicates the event
Johansen estimator22 P

times and I denotes the identity matrix (in this case a 7 x 7 matrix). The

multistate model was used to calculate probabilities for transplant and waitlist
dropout (terminal states) for each risk category (transient states). The model
accounts for transitioning between these states prior to dropout or transplant, as
well as transitioning directly to the terminal states.
Dropout and transplant probabilities were modeled for HCC patients. One
model was fitted for HCC patients stratified by laboratory MELD ranges for
evaluation of the six-month delay and another with stratification using MELD EQ .
A similar model was constructed for non-HCC patients. Actual dropout and
transplant probabilities were obtained from these models.
To address the possible concern of early transplant of high-risk HCC
patients who may have worse post-transplant outcomes, we compared posttransplant survival between high-risk HCC patients (MELD EQ ≥28) transplanted
within six months from listing and those transplanted after six months. KaplanMeier survival estimates and the log-rank test were used for this comparison.
All data analysis and statistical calculations were performed using SAS
(Version 9.4, Cary, NC) and R for Windows (Version 3.2.2).
Projected Outcomes
The projection estimates assume that HCC and non-HCC patients with the
same MELD / equivalent MELD strata are transplanted at the same rate. This is
similar to the projection method described in the original MELD EQ paper15,
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however here we modify the approach to account for the potential impact on nonHCC patients as well. This is done by assuming that the total number of
available organs remains fixed, and organs are redistributed across strata
according to non-HCC rates. The technical details for the projection method are
given below.
Projected transplant hazard rates were obtained based on current nonHCC transplant rates for each MELD / MELD EQ stratum 𝑖𝑖, 𝑖𝑖 = 1, … , 5, in the

following manner (recall that the strata are defined as MELD / MELD EQ score
HCC
(𝑡𝑡) be the total
ranges of <12, 12-15, 16-21, 22-27, and 28-40). Let 𝑑𝑑𝑑𝑑𝑖𝑖7

number of transplants to HCC patients in stratum 𝑖𝑖 at time t (here t = time since
nHCC
(𝑡𝑡) be analogously defined for
listing in our multi-state model) and let 𝑑𝑑𝑁𝑁𝑖𝑖7

non-HCC patients (recall that state 7 is the transplantation state in our model,
see Figure 1). For non-HCC patients being transplanted at time t, the
conditional probability that the organ goes to the 𝑖𝑖th strata is

nHCC
nHCC
(𝑡𝑡)�∑5𝑘𝑘=1 𝑑𝑑𝑑𝑑𝑘𝑘7
(𝑡𝑡). In the projections, these conditional
𝑝𝑝𝑖𝑖 (𝑡𝑡) = 𝑑𝑑𝑁𝑁𝑖𝑖7

probabilities for non-HCC patients are used to determine the probability that a
transplanted organ at time t goes to the 𝑖𝑖th strata. Let the total number of organs
(combined HCC and non-HCC) being transplanted at time t be 𝑑𝑑𝑁𝑁∙7 (𝑡𝑡) =

nHCC
HCC
∑5𝑘𝑘=1 � 𝑑𝑑𝑑𝑑𝑘𝑘7
(𝑡𝑡) + 𝑑𝑑𝑑𝑑𝑘𝑘7
(𝑡𝑡)�. Then the redistributed number of organs going

�𝑖𝑖7 (𝑡𝑡) =
to each strata (HCC and non-HCC combined) at time t are defined as 𝑑𝑑𝑁𝑁
𝑑𝑑𝑁𝑁∙7 (𝑡𝑡)𝑝𝑝𝑖𝑖 (𝑡𝑡). The fractions of these going to HCC and non-HCC patients are

determined by the relative number at risk in each group at that time. That is, the
projected number of organs going to HCC patients in stratum 𝑖𝑖 at time t is
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𝑌𝑌𝑖𝑖HCC (𝑡𝑡)

HCC
�𝑖𝑖7
𝑑𝑑𝑁𝑁
(𝑡𝑡) = �

𝑌𝑌𝑖𝑖HCC (𝑡𝑡)+ 𝑌𝑌𝑖𝑖nHCC (𝑡𝑡)

�𝑖𝑖7 (𝑡𝑡), where 𝑌𝑌𝑖𝑖HCC (𝑡𝑡) is the number of HCC
� 𝑑𝑑𝑁𝑁

patients in stratum 𝑖𝑖 just prior to time t and 𝑌𝑌𝑖𝑖nHCC (𝑡𝑡) is analogously defined for

non-HCC patients. Similarly, for non-HCC patients the projected number would
𝑌𝑌𝑖𝑖nHCC (𝑡𝑡)
HCC (𝑡𝑡)+ 𝑌𝑌 nHCC (𝑡𝑡)
𝑌𝑌𝑖𝑖
𝑖𝑖

nHCC
�𝑖𝑖7
be 𝑑𝑑𝑁𝑁
(𝑡𝑡) = �

�𝑖𝑖7 (𝑡𝑡).
� 𝑑𝑑𝑁𝑁

Once the projected number of transplanted organs are calculated for both

HCC and non-HCC patients for every stratum 𝑖𝑖 and time t, projected transplant
HCC
� HCC
(𝑡𝑡) and 𝑑𝑑𝐴𝐴̃nHCC
(𝑡𝑡) =
rates can be calculated as 𝑑𝑑𝐴𝐴̃HCC
𝑖𝑖7 (𝑡𝑡) = 𝑑𝑑𝑁𝑁𝑖𝑖7 (𝑡𝑡)�𝑌𝑌𝑖𝑖
𝑖𝑖7

nHCC
�𝑖𝑖7
(𝑡𝑡)�𝑌𝑌𝑖𝑖nHCC (𝑡𝑡). These transplant rates are substituted into the estimated
𝑑𝑑𝑁𝑁

� (𝑡𝑡) defined previously. Denote these matrices
state transition intensity matrix 𝑑𝑑A

with the substituted projected transplant rates for HCC and non-HCC patients as
� HCC (𝑡𝑡) and 𝑑𝑑𝑨𝑨
� nHCC (𝑡𝑡), respectively. Diagonal elements of I + 𝑑𝑑𝑨𝑨
� (𝑡𝑡) are
𝑑𝑑𝑨𝑨
adjusted accordingly so that each row sums to one. Then the projected

transplant and dropout probabilities can be calculated using the Aalen-Johansen
� HCC (𝑠𝑠, 𝑡𝑡) =
estimator with these newly defined transition intensity matrices as 𝑷𝑷
� HCC (𝑢𝑢)� and 𝑷𝑷
� nHCC (𝑢𝑢)�.
� nHCC (𝑠𝑠, 𝑡𝑡) = ∏𝑢𝑢 ∈(𝑠𝑠,𝑡𝑡]�I + 𝑑𝑑𝑨𝑨
∏𝑢𝑢 ∈(𝑠𝑠,𝑡𝑡]�I + 𝑑𝑑𝑨𝑨

The projected transplant hazards were calculated as above for both the

six-month delay model and the MELD EQ model. For projections under the sixmonth delay, use of the actual transplant hazards in the Aalen-Johansen
estimator were resumed after six months to reflect reverting to scheduled
exception point progression. For projections under the MELD EQ , the probabilities
were calculated using projected transplant hazards through 18 months.
To project outcomes for patients under the MELD EQ given a patient is still
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on the list after 6 months, separate calculations were made for 6-18 months from
listing. Calculations were made in an analogous fashion using the non-HCC
multistate model, the MELD EQ HCC multistate model, and projected transplant
hazards as described in the previous paragraphs. However, transition times
starting at six months from listing were used.
Overall projected and actual dropout and transplant probabilities at six, 12
and 18 months since time of listing were calculated using the multistate models
for the six-month delay, the MELD EQ and the prioritization scheme in place
during the time of the study. The variances of these estimates for actual
probabilities were obtained using the bootstrap option in the R package
msSurv21, with 200 iterations, and used to construct normal 95% confidence
intervals. For projected overall probabilities, 500 bootstrap iterations of the
projected estimates were performed and checked graphically for normality. Then
their standard deviations were used to construct normal 95% confidence
intervals.
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Figure 1: Schematic Diagram of Multistate Model. Transient states consisting
of MELD or MELD EQ ranges are represented by circles, while the terminal states
of dropout and transplant are represented by rectangles. Transitions are possible
between any of the transient states (light lines), and from any transient state to
the terminal states (bold lines). Transitions to the dropout / transplant states are
of primary interest.
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RESULTS
A total of 7,931 patients were listed with HCC exceptions and 34,868
patients with standard MELD scores during the time frame between 10/1/2009
and 6/30/2014. Three HCC patients were missing HCC-related covariate data,
leaving 7,928 for analysis. Table 1 shows the numbers and percentages of HCC
and non-HCC patients who were censored, dropped out, received transplant, or
improved as of last follow-up. Compared to non-HCC, HCC patients had a higher
percentage of transplantation (71% vs. 39.9%) and a lower percentage of
dropout (5.7% vs. 10.6%).

Outcome
Censored
Dropout
Transplanted
Improved
Total

HCC
Count (percent)
1837 (23.2%)
452 (5.7%)
5629 (71%)
10 (0.1%)
7928

Non-HCC
Count (percent)
16633 (47.7%)
3700 (10.6%)
13895 (39.9%)
640 (1.8%)
34868

Table 1: Outcomes at last follow up for HCC and non-HCC patients. Numbers in
each cell are the count and percentage of patients out of 7928 total HCC patients
and 34868 non-HCC patients.

Figure 2 displays actual and projected dropout and transplant probabilities
for patients stratified by their laboratory MELD ranges during 0-18 months from
listing. As expected, the transplant probabilities under recent practice are similar
for HCC patients regardless of MELD score range (Figure 2a). There is some
differentiation in actual dropout probabilities for HCC patients stratified by
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laboratory MELD, though not as clear as that for non-HCC patients (Figure 2c).
The separation in projected transplant probabilities by dropout risk strata under
the six-month delay is much more distinct than before, though lower than the
corresponding non-HCC patients in the same ranges (Figure 2b) for the first six
months. We see an increase in projected transplant probabilities compared to
actual for HCC patients in strata with MELD scores >21 for the first 6 months, but
a decrease for those in lower strata (c.f. Figure 2a vs. 2b). However, after six
months, projected transplant probabilities rapidly increase for HCC patients to
again exceed those for non-HCC patients (Figure 2b). Under the delay, dropout
probabilities for HCC patients with MELD scores <22 are projected to be slightly
higher compared to current levels (c.f. Figure 2d vs. 2c) though patients with
higher MELD scores are expected to have reduced dropout probabilities relative
to current. Projected dropout probabilities are also somewhat higher for HCC
patients with MELD scores <22 relative to non-HCC patients, but lower for HCC
than non-HCC for patients with MELD scores ≥22. For non-HCC patients,
dropout probabilities are projected to be slightly reduced for those with MELD
>15 (c.f. Figure 2c vs. 2d).
Projections under MELD EQ are very similar to those for the six-month
delay for the first six months of listing, as seen by comparing Figures 2 and 3 for
the first six months shown. During these first six months, the MELD EQ score is
equivalent to the laboratory MELD score for 93% of observations. Table 2 shows
the distributions of the MELD EQ and laboratory MELD for HCC patients at listing.
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Score Ranges
6-11
12-15
16-21
22-27
28-40

HCC MELD EQ
Count (percent)
4759 (60.0%)
2075 (26.2%)
959 (12.1%)
126 (1.6%)
9 (0.1%)

HCC Lab MELD
Count (percent)
4889 (61.7%)
2017 (25.4%)
911 (11.5%)
102 (1.3%)
9 (0.1%)

Table 2: Frequency distributions of the MELD EQ and laboratory MELD
scores for HCC patients at initial listing. Numbers in each cell are the count and
percentage of patients out of 7928 total HCC patients.

Figure 3 shows actual and projected dropout and transplant probabilities
under the MELD EQ scoring method through 18 months from listing. At six
months, a slight increase in projected HCC transplant probabilities is seen under
this scheme similarly to the six-month delay, but the increase is much less
pronounced. This increase would be expected as the MELD EQ assigns 6.85
more points when a patient has been on the waiting list for at least six months.
As with laboratory MELD, actual transplant probabilities are similar over
time for all HCC patients regardless of risk strata as determined by the MELD EQ
(Figure 3a). Under the MELD EQ model, projected transplant probabilities are
much more defined according to risk strata (Figure 3b), and thus closer to nonHCC probabilities compared to actual transplant probabilities for most strata. In
contrast to Figure 2b, they remain this way after six months on the waitlist.
However, they are less than projected non-HCC probabilities in the
corresponding strata. Non-HCC transplant probabilities are projected to increase
slightly for all strata under this model (c.f. Figure 3a vs. 3b), while non-HCC
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dropout would decrease slightly for all but the lowest stratum (c.f. Figure 3c vs
3d). Under the MELD EQ , dropout probabilities are projected to increase for those
with scores <22 and decrease for those with scores ≥22 (Figures 3c and 3d).
Figure 4 shows actual and projected transplant and dropout probabilities
for HCC patients stratified by MELD EQ scores and non-HCC by MELD scores for
six months through 18 months after listing. These curves reflect the probability of
transplant or dropout for a patient given she/he is still on the waitlist at six
months. During this time frame, actual transplant probabilities (shown in Figure
4a) for HCC patients exceed those for non-HCC patients except for the highest
non-HCC risk group (MELD≥28). Projected transplant probabilities under the
MELD EQ match those for non-HCC patients in corresponding ranges well (Figure
4b). Projected dropout probabilities for HCC patients under this scheme exceed
the levels for the corresponding non-HCC strata (Figure 4d). Compared with
actual dropout (Figure 4c), projected probabilities would again be reduced for
HCC patients with MELD EQ scores ≥22 but increased for those with scores <22.
For non-HCC patients, projected dropout probabilities are similar to actual for
MELD <16 and reduced for MELD ≥16. The projections on Figure 4 reflect
dropout and transplant probabilities under the MELD EQ as if it were used
beginning at six months waitlist time. The results displayed in Figures 2 and 3
are aggregated and summarized in Table 3, which gives overall dropout and
transplant probabilities and their 95% confidence intervals under recent practice
(“actual” on Figure 3) and projected for the six-month delay and the MELD EQ at
6, 12 and 18 months after listing. Under the six-month delay, overall dropout at 6
months is projected to increase slightly for HCC patients and decrease slightly for
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non-HCC patients compared to actual probabilities, as expected, while overall
transplant probabilities would be reduced for HCC patients and increased for
non-HCC patients. As noted previously, these results are very similar for the
MELD EQ during the first six months on the waitlist.
At 12 months waitlist time, the overall dropout probability would increase
somewhat for HCC patients under both the six-month delay and the MELD EQ ,
while it would decrease for non-HCC patients. This change is slightly greater
under the MELD EQ . Again, the opposite change would be seen for transplant
probabilities (increase for non-HCC and decrease for HCC) under these
schemes. This change is more pronounced under the MELD EQ . The same trend
is seen at 18 months waitlist time. For all of these probabilities, the point
estimates and 95% confidence intervals are shown in Table 3.
Table 3c shows actual and projected dropout probabilities for total HCC
and non-HCC patients, weighted by the proportion of each group to the whole
sample. Both the six-month delay and the MELD EQ are projected to decrease
total dropout probabilities compared to actual, though in neither case is the result
statistically significant as indicated by the overlap in 95% confidence intervals
(CIs). While the total projected dropout is nearly identical between the MELD EQ
and the six-month delay at the various time points, the probabilities become
closer over time between HCC and non-HCC patients under the MELD EQ (see
Table 3a and 3b). At 12 months, projected dropout probabilities under the
MELD EQ are 8.38% and 8.89% for HCC and non-HCC respectively, and at 18
months they are 10.82% and 10.22%. Under the six-month delay, overall
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projected dropout for non-HCC patients is still statistically significantly higher
than that for HCC patients at these time points (95% CIs do not overlap).

Actual
6
Mo
12
Mo
18
Mo

3.68%
3.25, 4.11
5.63%
5.11, 6.15
6.42%
5.85, 6.99

Actual
6
Mo
12
Mo
18
Mo

6
Mo
12
Mo
18
Mo

7.71%
7.41, 8.01
10.15%
9.78, 10.52
11.9%
11.51,12.29

Dropout
6-Month
Delay

a. HCC Patients

Transplant
6-Month
Delay

MELD EQ

Actual

4.58%
4.02, 5.15
7.73%
6.94, 8.52
9.02%
8.13, 9.91

4.54%
3.98, 5.1
8.38%
7.49, 9.28
10.82%
9.63,12.01

43.33%
42.21, 44.45
66.29%
65.18, 67.4
80.97%
79.92, 81.95

Dropout
6-Month
Delay

b. Non-HCC Patients
Transplant
MELD EQ
Actual
6-Month
Delay

7.01%
6.74, 7.27
9.1%
8.79, 9.42
10.7%
10.34,11.05

Actual

6.96%
6.64, 7.29
9.31%
8.92, 9.71
10.88%
10.46, 11.31

7.01%
6.75, 7.28
8.89%
8.59, 9.2
10.22%
9.89,10.56

35.95%
35.45, 36.45
42.74%
42.17, 43.31
46.4%
45.76, 47.04

8.18%
7.76, 8.61
45.92%
44.33, 47.52
70.2%
68.53, 71.88

41.19%
40.66, 41.72
46.84%
46.31, 47.37
50.1%
49.56, 50.65

MELD EQ
8.54%
8.11, 8.97
16.5%
15.82, 17.17
21.63%
20.73, 22.53

MELD EQ
41.14%
40.62, 41.67
49.77%
49.25, 50.29
54.49%
53.96, 55.02

c. Total (HCC and non-HCC) Dropout
6-Month Delay
MELD EQ
6.56%
6.24, 6.88
8.85%
8.45, 9.25
10.39%
9.93, 10.84

6.55%
6.24, 6.87
8.8%
8.39, 9.21
10.33%
9.84, 10.83

Table 3: Overall dropout/transplant probabilities with 95% confidence intervals
for HCC and non-HCC patients, actual and projected with prioritization under the
6-month delay and MELD EQ at 6, 12, and 18 months waitlist time.
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Figure 2: Actual and projected time to transplant and dropout for HCC and
non-HCC patients stratified by laboratory MELD score. Time is from 0 to 18
months after listing. Solid lines indicate the probability of transplant/dropout for
HCC patients under the current scheme (a,c) and under the six-month delay in
assigning exception points (b, d). Dashed lines indicate the corresponding
probability curves for non-HCC patients. The number at risk for HCC patients at
baseline, 6, and 12 months is given in the upper part of panel c.
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Figure 3: Actual and projected time to dropout or transplant for HCC
patients stratified by MELD EQ score and non-HCC patients by MELD. Time
is from 0-18 months after listing. The curves reflect the probability of transplant or
dropout under the current scheme (a, c) and those projected under the MELD EQ
scoring system (b, d). Solid lines represent probabilities for HCC patients while
dashed lines represent those for non-HCC patients. The number at risk for HCC
patients at baseline, 6, and 12 months is given in the upper part of panel c.
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Figure 4: Actual and projected time to dropout or transplant for HCC
patients stratified by MELD EQ score and non-HCC patients by MELD. Time
is from 6 months until 18 months after listing. The curves reflect the probability,
given a patient is still on the waiting list at 6 months, of transplant or dropout
under the current scheme (a, c) and those projected under the MELD EQ scoring
system (b, d). Solid lines represent probabilities for HCC patients while dashed
lines represent those for non-HCC patients. The number at risk for HCC patients
at 6, 9, 12, and 15 months is given in the upper part of panel c.
32

Lastly, since part of the rationale of the six month delay was to possibly
avoid transplanting high-risk HCC patients earlier who may have poorer
outcomes, post-transplant survival was compared between patients classified as
higher-risk (MELD EQ ≥28) and transplanted within six months (n=26) vs. after six
months (n=81) from listing. Although post-transplant survival was somewhat
lower for those transplanted earlier, this was not statistically significant (p=0.285).

DISCUSSION
In this part of the study, projections were evaluated for dropout and
transplant probabilities under the recently implemented six-month delay for
granting exception MELD points to HCC patients and compared to prioritization
based on the MELD EQ . While the six-month delay will improve equity of
transplant probabilities between HCC and non-HCC patients for the first six
months on the waiting list, these results show that reverting to scheduled
exception point progression after six months will again advantage HCC patients.
Additionally, reverting to exception points after six months still treats all HCC
patients as having the same dropout risk regardless of tumor characteristics or
laboratory MELD.
Dropout was projected to increase under the delay for HCC patients with
MELD scores <22, but projected to decrease for both HCC and non-HCC
patients with MELD scores ≥22. This increase in dropout for lower HCC risk
groups is in contrast to findings in the original study describing the derivation of
the MELD EQ

15

. In that study, it was projected that patients with MELD EQ scores

≤15 would not be adversely affected by the six-month delay while those with
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higher scores could be adversely affected in terms of dropout probability. It was
noted that the advantage to HCC patients was not universal, as dropout
probabilities for lower risk HCC patients (MELD EQ ≤15) were lower than their nonHCC counterparts while their transplant probabilities were higher. The opposite
(higher dropout, lower transplant) was true for patients in higher MELD EQ ranges.
While this appears to still be the case for transplant probabilities, dropout for
most HCC groups in the current study appears to be lower than in the original
MELD EQ study. Overall HCC dropout probabilities in the current study were
found to be 3.68% at 6 months and 5.63% at 12 months while in the earlier study
they were 4.7% at 6 months and 7.2% at 12 months 15. Also, since the original
MELD EQ study modeled dropout and transplant since the time a patient first
entered a score range and the MELD EQ assigns more points once a patient has
been on the waitlist for six months, it is likely that some of the higher risk patients
identified in the earlier study had already been on the list for six months or more.
In order to make comparisons with the six-month delay, in this study we modeled
these probabilities using time since listing.
While dropout probabilities were projected to increase somewhat for HCC
patients under both the six-month delay and the MELD EQ , the magnitude of this
increase was much smaller than that of the projected decrease in HCC transplant
probabilities. This was particularly evident under the MELD EQ . Results from the
paper by Heimbach et al also suggested that increased mortality rates may not
accompany decreased transplant rates for HCC patients 10. However, the
reduction of HCC transplant probabilities below those of non-HCC candidates is
still a limitation of the MELD EQ , as ideal prioritization would equalize both
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transplant and dropout probabilities between HCC and non-HCC patients overall
and according to dropout risk strata.
Other investigators have looked at the balance between waiting time,
waitlist dropout, post-transplant survival and equity of transplant rates, and found
that increased waiting time was associated with either improved overall survival
(while on the waiting list and post-transplant) or post-transplant survival 23-25. The
possible benefits and risks of increased waiting time were also discussed in a
paper by Roayaie & Roayaie, who point out that while increased waiting time was
associated with longer post-transplant survival, waiting too long begins to remove
patients who would have done well post-transplant 26. While findings here include
slightly lower post-transplant survival for HCC patients transplanted earlier
versus later, this result was not statistically significant. It should be noted that
this comparison was only made for patients with MELD EQ of at least 28 at their
last follow up prior to transplant, which was a small sample size (n=107).
Increased waiting time was not the primary goal of the MELD EQ , though it does
assign a higher score once a candidate has been on the list for six months.
A limitation of this study is that the representation of organ availability
used in the projections may not be completely realistic since projections were
modeled using time since listing rather than calendar time. That is, the number of
organs estimated to be available at a certain time t is based on how many
candidates received an organ at that time t since listing. However, this method
still provides an estimate of the proportion of transplants going to each group and
the projected change for HCC relative to non-HCC candidates under each
prioritization system. Also, evaluating three prioritization systems this way can
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still provide a valid comparison of them, as they were all compared using the
same projection method.
Strengths of the study include examination of the effects of the six-month
delay and the MELD EQ over time, including projections after six months on the
waitlist, and study of these effects among different HCC dropout risk strata. While
equalizing HCC and non-HCC dropout and transplant probabilities overall is the
primary goal, part of this goal is to prioritize those patients who most urgently
need and can benefit the most from transplantation. Studying outcomes for each
stratum based on a score utilizing HCC characteristics can help identify those
patients and help to further calibrate HCC-based scores.
In conclusion, despite improvement in equity for the first six months under
the delay, reverting to scheduled exception point progression after six months
continues to advantage HCC patients. Thus an HCC-specific prioritization
method, particularly for use after six months, is still needed. Utilizing the
MELD EQ after six months would improve equity of transplant probabilities
between HCC and non-HCC patients, and its use through six months yields
results similar to those of the six-month delay. Further, while overall projected
dropout probabilities were nearly identical for the MELD EQ and 6-month delay,
projected differences between HCC and non-HCC patients were smaller under
the MELD EQ . However, using the MELD EQ is projected to increase dropout
beyond non-HCC probabilities for some HCC risk strata. Therefore, further
adjustment of the score would be needed before consideration for use in
practice.
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CHAPTER 3
MELD EQ AND deMELD COMPARISON
For this study, two of the aforementioned equivalent MELD scores, the
MELD EQ

15

and the mixed new dropout equivalent MELD 13 (referred to in this

chapter as simply “deMELD”) were evaluated. Recall from Chapter 1 that these
scores were derived by determining dropout probabilities or hazards based on
established HCC characteristics as well as laboratory MELD, and then equating
these HCC probabilities or hazards to those of non-HCC patients to find the
corresponding MELD score. Both deMELD and MELD EQ scores could be used
for HCC patients comparably to the laboratory MELD for non-HCC patients since
they are on the same scale. The deMELD was designed according to the
probability of dropout from the waiting list while the MELD EQ equated dropout
hazards.
The primary aims of the current study were to compare the predictive
accuracy for waitlist dropout of both scores and to evaluate possible effects of
prioritization with these scores on waitlist dropout and transplant probabilities.
These outcomes were studied in both original publications 13,15, but the intent
here was to validate the scores with newer data and to compare the scores with
each other. Secondary goals were to study how changes in HCC-related
covariates affected both alternative MELD scores, and compare post-transplant
survival between patients in various ranges of the scores.

37

METHODS
The same datasets for HCC and non-HCC patients as described in
Chapter 2 were used for this study as well.
Outcomes and Covariates
The main outcomes studied included actual dropout and transplant
probabilities for HCC patients under the scheduled progression in place during
the timeframe of the study compared to those of non-HCC patients and those
probabilities projected under the deMELD and MELD EQ . Also, post-transplant
survival of patients stratified by ranges of the two alternative scores was
evaluated. In addition, the effect of differences in the included covariates on
categorization by the two alternative scoring models was examined. The
covariates from these two models were alpha-fetoprotein (AFP) or the natural log
of AFP, laboratory MELD, maximum tumor size, and number of tumors.
Additionally, the MELD EQ calculation includes a constant which increases when
waitlist time reaches six months.
Dropout, transplant and censored were defined in the same manner as the
study described in Chapter 2.
Statistical Methods
All data analysis and statistical calculations were performed using SAS
(Version 9.4, Cary, NC) and R (Version 3.1.1). The MELD EQ and deMELD were
calculated for each observation of HCC patients in the dataset using the following
equations:
MELD EQ =

max(lab MELD, 1.143*MELD + 1.324*ln (AFP)
+ 1.438*Number of Tumors + 1.194*Max Tumor Size + c(t) ),
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where c(t) = -2/0.146 for t<6 months and c(t)= -1/0.146 for
t≥6 months
deMELD =

max(lab MELD, -37.8 + 1.9*MELD
+ 5.9 if Number of Tumors ≥2
+ 21.2 if Max Tumor Size >1 cm + 5.9 if AFP>400)

AFP values less than 1 were taken to be 1 for the purpose of calculating
ln(AFP). The observations were then categorized into ranges based on their
MELD EQ and deMELD. These ranges included <12, 12-15, 16-18, 19-21, 22-24,
25-30, 31-35, and 36-40. These categories were then used as the transient
states in nonparametric multistate models for dropout and transplant
probabilities, using the R package msSurv. The multistate model is discussed in
detail in the paper describing the msSurv package by Ferguson et al 21. Figure 5
depicts a diagram of the multistate model used for this study. This is similar to
the multistate model used in Chapter 2, but this model has eight transient states
since eight risk strata were created as described above. The terminal states
again are dropout and transplant.
Time zero was taken to be time first entering a given score range. This
approach was used because clinically, projections for a patient given their current
score or risk level are of interest in addition to their risk at listing. Also, very few
patients were categorized in the highest risk groups at listing by either alternative
score, as shown in Table 4.
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Figure 5: Schematic Diagram of Multistate Model. Transient states consisting
of MELD or alternative MELD ranges are represented by ovals, while the terminal
states of dropout and transplant are represented by rectangles. Transitions are
possible between any of the transient states and another transient state (light
lines), and from any transient state to the terminal states (bold lines). Transitions
to the dropout / transplant states are of primary interest.
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Score
Ranges
6-11
12-15
16-18
19-21
22-24
25-30
31-35
36-40

HCC MELD EQ
Initial listing
Last follow-up
4759 (60.0)
4081 (51.5)
2075 (26.2)
2021 (25.5)
692 (8.7)
933 (11.8)
267 (3.4)
469 (5.9)
103 (1.3)
226 (2.9)
29 (0.4)
155 (2.0)
1 (0.01)
32 (0.4)
2 (0.03)
11 (0.1)

deMELD
Initial Listing Last follow-up
4861 (61.3)
4580 (57.8)
1803 (22.7)
1814 (22.9)
676 (8.5)
766 (9.7)
250 (3.2)
279 (3.5)
160 (2.0)
222 (2.8)
134 (1.7)
173 (2.2)
31 (0.4)
56 (0.7)
13 (0.2)
38 (0.5)

Table 4. Frequency distributions of the MELD EQ and deMELD scores for HCC
patients at first listing and at last follow-up on the waitlist. Numbers in each cell
are the count and percentage of patients out of 7928 total HCC patients.

To project dropout and transplant probabilities based on the proposed
schemes, the same multistate model was constructed for non-HCC patients
using analogous laboratory MELD score ranges, and the transplant hazard rates
from the non-HCC model were substituted into the HCC models for groups in the
same MELD EQ and deMELD ranges. This is the same procedure that was used
in the original paper describing the MELD EQ

15

. These were then used to project

transplant probabilities using the Aalen-Johansen estimator 21,22.
To compare equity of projected HCC dropout and transplant under the
equivalent MELD models with that of non-HCC patients, matching of projected
HCC transplant and dropout probabilities under each scheme to non-HCC
probabilities was assessed graphically. Projected dropout was also assessed
numerically for each stratum. The absolute value of the difference between nonHCC probabilities and projected HCC dropout probabilities was calculated.
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Similarly, the relative difference was calculated as a proportion of non-HCC
probabilities. These absolute and relative differences were then averaged over
all times through one year. To obtain an overall estimate of projected
comparability to non-HCC probabilities for each score, an average of these
absolute and relative differences was taken at each time, weighted by the
proportion in each stratum of the number at risk at that time. These results were
then averaged over all times through one year. Since the absolute value of these
differences represents HCC dropout either exceeding or not reaching non-HCC
dropout, a smaller value indicates better equality with non-HCC dropout
probabilities.
Using the described score ranges, differences in the way the two
alternative scores classified patients were explored by comparing the values of
patient covariates for those observations where the alternative score categories
agreed with those observations where they did not. The concordance index was
also used to compare overall predictive accuracy for waitlist dropout 27 between
the two scores. Lastly, we compared post-transplant survival between the
various risk groups as determined by both scores using Kaplan-Meier curves and
Cox proportional hazard models.

RESULTS
A total of 7,928 HCC and 34,868 non-HCC patients were studied as in
Chapter 2. Table 4 shows the distributions of the two scores at initial listing and
last follow-up. The overall C-indices for HCC waitlist dropout were 0.586 (95%
CI: 0.562, 0.61) for exception MELD scores, 0.653 (95% CI: 0.624, 0.682) for
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laboratory MELD, 0.678 (95% CI: 0.649, 0.707) for MELD EQ and 0.664 (95% CI:
0.635, 0.693) for deMELD. In comparison, the C-index for non-HCC waitlist
dropout was 0.832 (95% CI: 0.822, 0.842) for MELD.
To assess the agreement in actual dropout probabilities between nonHCC patients and HCC patients stratified by the MELD EQ , Figures 6a and 7a
compare actual dropout probabilities for HCC patients stratified by MELD EQ
ranges to that of non-HCC patients in corresponding MELD ranges. For the
lower risk categories (scores <22) shown in 6a, the MELD EQ matches non-HCC
dropout fairly well until about 6 months from entering a state and then begins not
to reach non-HCC dropout probabilities, especially for the 16-18 and 19-21 score
ranges. As shown on Figure 7a, the actual dropout probability curve for the
MELD EQ 22-24 group matches the corresponding non-HCC curve well at most
times, but matching is poor for groups with MELD EQ scores above 24. There is
some matching for the 36-40 group but data are sparse in this range.
A similar assessment of agreement in actual dropout probabilities was
performed for the deMELD (Figures 8a and 9a). The deMELD showed good
matching through about eight months from entering a state for scores <22
(Figure 8a). Matching of actual dropout probabilities to corresponding non-HCC
ranges is somewhat better under the deMELD than the MELD EQ for scores less
than 22. Matching is poor under deMELD for groups with scores greater than 21
(Figure 8a). Again, data are sparse for the higher risk groups, especially as
stratified by the MELD EQ . This can be seen in the numbers at risk shown in
Figures 7a and 9a.
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Projected dropout probabilities are increased beyond target non-HCC
levels for groups in the lower risk ranges (MELD EQ and deMELD <16) under both
alternative scores (see Figures 6b and 8b), though to a lesser degree for
deMELD 12-15 (Figure 8b). However, dropout would decrease for those with
alternative MELD scores ≥22 (Figures 7b and 9b), to a lesser degree for
MELD EQ 22-24. Actual dropout is already lower than non-HCC for most of these
strata (Figures 7a and 9a). Actual and projected dropout probabilities appear
especially low for deMELD ≥22 (Figures 9a and 9b).
Table 5 displays absolute and relative differences by stratum and overall
average difference (weighted by strata) between non-HCC dropout and projected
HCC dropout under each equivalent MELD score if implemented. Matching to
non-HCC dropout probabilities is similar between the deMELD and the MELD EQ
for equivalent scores <12, 16-18, and 31-35. Matching is better for deMELD
scores of 12-15 (absolute difference of 0.00647 vs. 0.01152 for MELD EQ ) and 1921 (0.00564 vs 0.00745 for MELD EQ ). Matching is better for MELD EQ scores of
22-24 (0.01178 vs. 0.04148 for deMELD), 25-30 (0.04693 vs. 0.06388 for
deMELD), and 35-40 (0.06820 vs. 0.15135 for deMELD). The weighted overall
difference is very similar between the two scores.
Projected transplant for both scores (Figures 6-9, panel d) shows better
stratification based on risk level than actual transplant probabilities (Figures 6-9,
panel c), especially for the lower risk groups, although lower than target nonHCC probabilities for most groups. The MELD EQ matches non-HCC transplant
probabilities slightly better than the deMELD for equivalent scores 12-15 and
similarly to the deMELD for scores <12 and 16-18. The deMELD score matches
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non-HCC transplant probabilities better than the MELD EQ for scores >18 and
particularly scores ≥31. However, neither score matches especially closely for
the range of 19-30 (Figures 6-9, panel d).

Equivalent
MELD
Score
Range
<12
12-15
16-18
19-21
22-24
25-30
31-35
35-40
Overall

MELD EQ
Difference from non-HCC
Absolute
Relative
0.01002
39.7%
0.01152
29.8%
0.00236
6.9%
0.00745
9.5%
0.01178
12.0%
0.04693
37.4%
0.09742
63.4%
0.06820
35.9%
0.01030
32.0%

deMELD
Difference from non-HCC
Absolute
Relative
0.01049
41.4%
0.00647
18.4%
0.00239
6.9%
0.00564
9.4%
0.04148
38.9%
0.06388
50.4%
0.09372
60.6%
0.15135
75.8%
0.01034
32.6%

Table 5. Average absolute and relative differences between non-HCC and
projected HCC dropout probabilities under MELD EQ or deMELD by range of each
equivalent MELD score. The absolute differences are the absolute values of the
difference between the projected HCC dropout curves and non-HCC actual
dropout curves depicted in Figures 6b, 7b, 8b and 9b. The relative differences
are those absolute differences as a proportion of actual non-HCC dropout
probabilities. Smaller values indicate closer matching between the equivalent
MELD range and the target non-HCC MELD range. The overall differences
weighted by number at risk in each stratum and averaged over all times through
365 days are shown in the bottom row. The number at risk is shown for 0, 3, 6
and 9 months on Figures 6a, 7a, 8a and 9a, though for this calculation the
number at risk at each time from 1 to 365 days was used.
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Figure 6: Actual and projected time to dropout/transplant for lower-risk
(MELD EQ <22) HCC patients stratified by MELD EQ score. Time is from entry
into the corresponding MELD EQ range for HCC patients or the MELD range for
non-HCC patients. Solid lines indicate probablity of transplant/dropout for HCC
patients, whereas dashed lines indicate corresponding probability curves (actual
only) for non-HCC patients. The number at risk for HCC patients at 0, 3, 6, and 9
months is given in panel a. The predictions pertain only to HCC patients; for
non-HCC patients only actual probability curves are given.
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Figure 7: Actual and projected time to dropout/transplant for higher-risk
(MELD EQ ≥22) HCC patients stratified by MELD EQ score. Time is from entry
into the corresponding MELD EQ range for HCC patients or the MELD range for
non-HCC patients. Solid lines indicate probablity of transplant/dropout for HCC
patients, whereas dashed lines indicate corresponding probability curves (actual
only) for non-HCC patients. The number at risk for HCC patients at 0, 3, 6, and 9
months is given in panel a. The predictions pertain only to HCC patients; for
non-HCC patients only actual probability curves are given.

47

Figure 8: Actual and projected time to dropout/transplant for lower-risk
(deMELD<22) HCC patients stratified by deMELD score. Time is from entry
into the corresponding deMELD range for HCC patients or the MELD range for
non-HCC patients. Solid lines indicate probablity of transplant/dropout for HCC
patients, whereas dashed lines indicate corresponding probability curves (actual
only) for non-HCC patients. The number at risk for HCC patients at 0, 3, 6, and 9
months is given in panel a. The predictions pertain only to HCC patients; for
non-HCC patients only actual probability curves are given.
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Figure 9: Actual and projected time to dropout/transplant for higher-risk
(deMELD≥22) HCC patients stratified by deMELD score. Time is from entry
into the corresponding deMELD range for HCC patients or the MELD range for
non-HCC patients. Solid lines indicate probablity of transplant/dropout for HCC
patients, whereas dashed lines indicate corresponding probability curves (actual
only) for non-HCC patients. The number at risk for HCC patients at 0, 3, 6, and 9
months is given in panel a. The predictions pertain only to HCC patients; for
non-HCC patients only actual probability curves are given.
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Effect of Covariates on MELDEQ and deMELD
Table 6 shows a cross-tabulation of how each observation on the waiting
list was categorized by each alternative score. Risk groups with MELDEQ and
deMELD scores <19 had the most agreement between the two scores: the
majority of observations placed in these categories by one score were also
placed there by the other score. Table 7 shows summaries of the contributing
covariates for observations that were placed in the same category by both scores
and Table 8 shows those that were categorized differently by the two alternative
scores. This comparison was made when less than half the observations
assigned to a category by one alternative score were also assigned there by the
other score. For example, 411 observations had deMELD scores in the 36-40
range, and 93 (22.6%) of these also had MELDEQ scores of 36-40 (see Table 6).
Another 171 (41.6%) of them had MELDEQ scores of 25-30, so the covariates of
these 93 observations with score agreement were compared with those of the
171 observations with score disagreement.
As shown in Tables 7 and 8, in groups where the deMELD category
exceeded the MELDEQ category, less than half of observations had waitlist times
of six months or more, with the exception of the highest risk group (MELDEQ =
31-35 and deMELD = 36-40, n=147, Table 8). In contrast, for the groups in which
the MELDEQ was at least as great as the deMELD score (outside of scores in the
19-21 range), 71-94.4% of waitlist times were greater than 6 months. The
MELDEQ assigns 6.85 more points when waitlist time is at least six months, and
the deMELD does not include a term for time on the waitlist. Also, in the groups
for where the deMELD category exceeded the MELDEQ category, all
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observations had a maximum tumor size greater than 1 cm, which was not true
for categories with MELDEQ ≥ deMELD. A tumor size >1 cm adds 21.2 points to
the deMELD score, compared to 1.194 points for each cm increase for the
MELDEQ.
No obvious differences were noted in this comparison for number of
tumors or AFP, so the distribution of them in the dataset as a whole was
examined. For number of tumors, the deMELD assigns more points unless
there is only 1 tumor or greater than 4 tumors, since the deMELD assigns 5.9
points for ≥2 tumors and the MELDEQ assigns 1.438 points per tumor. However,
about 80% of observations in the dataset had only 1 tumor (note that each
patient can have multiple observations). Thus, for the majority of observations,
the MELDEQ was assigning 1.438 points for number of tumors while the deMELD
was assigning 0 points, which is not a large difference when considering the
other factors.
For AFP >1, the MELDEQ will assign more points than the deMELD, as the
deMELD gains 5.9 points if AFP >400, and 0 points otherwise. If AFP >400 this
term will be at least 7.93 for the MELDEQ: (ln(401) = 5.99 so the AFP term for
MELDEQ will be 5.99*1.324 = 7.93). However, if ln(AFP)=0, neither score will
gain points for AFP. Less than 25% of the observations in each group compared
had AFP levels >400, and less than 15% had ln(AFP) = 0. Thus, the MELDEQ
assigned points (approximately 1 to 8) for AFP to most observations while the
deMELD assigned 0 for most observations. In the entire dataset only 1698
(3.2%) of observations had AFP>400 and only 845 (1.6%) had ln(AFP)=0. The
median AFP in the dataset was 9, and the 75th percentile was 29, so half the
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observations would receive less than 2.9 points, and the majority would be
assigned less than 4.5 points by the MELD EQ for AFP.
For the laboratory MELD, it was noted that in the groups studied where
the deMELD category exceeded the MELD EQ category, none of the deMELD
scores matched the laboratory MELD. The converse was also true for the
category in which MELD EQ exceeded deMELD, but only one such category was
examined (Table 8). This is not surprising since each score takes the maximum
of the calculated score or the laboratory MELD (so a higher equivalent score
might already exceed the laboratory MELD). The deMELD assigns 1.9 points
and the MELD EQ assigns 1.143 points for every 1 point increase in laboratory
MELD.
Of the groups compared for score agreement, waitlist time and maximum
tumor size seemed to have the most effect, which is expected since these will
generally account for the biggest differential in contributions to each score.
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MELD EQ
Category
<12

deMELD Category
<12
27189
99.9%
89.9%

12-15

16-18

19-21

22-24

25-30

31-35

36-40

Row
Totals

2

0

0

0

0

0

27215
50.7%

13

0

0

0

13995
26.1%

342
1168
36.9%
60.8%

1
390
6.5%
31.8%

2

0

0

6020
11.2%

0

0

3162
5.9%

176
285
23.6%
52.1%
80
30.9%
14.6%

0
171
14.2%
41.6%
147
56.8%
35.8%
93
92.1%
22.6%
411
0.8%

12-15

2552

24
10640
76%
82.7%

16-18

409

1608

19-21

57

543

789
3269
54.3%
64%
747
23.6%
14.6%

22-24

12

55

261

297

337
383
22.3%
31.2%

25-30

12

0

42

102

116

310
530
30.9%
39.1%
480
39.7%
35.4%

31-35

0

0

0

0

1

31

36-40
Column
Totals

0
30231
56.3%

0
12870
24%

0
5110
9.5%

0
1922
3.6%

0
1228
2.3%

2
1355
2.5%

6
547
1%

1714
3.2%
1208
2.3%
259
0.5%
101
0.2%
53674

Table 6: Cross tabulation of equivalent MELD score assignments by
MELD EQ and deMELD. The numbers in each cell are the number of HCC
observations categorized by the deMELD score in the column heading and the
MELD EQ score in the row heading followed by the row percent and column
percent. The row and column totals shown include the percent of total
observations. Each individual patient can have multiple observations
representing different follow up times on the waiting list. The cells where scoring
systems agree are green, and those selected for comparison where scores do
not agree are red.
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MELD EQ and deMELD=36-40
n = 93 obs.
85 (91.4% )≥6 mo

MELD EQ and deMELD=31-35
n = 80 obs.
73 (91.3%) ≥6 mo

MELD EQ and deMELD=25-30
n = 480 obs.
408 (85% )≥6 mo

85 (91.4%) >1cm
8 (8.6%) were 0
Median size = 2.4 cm
45 (48.4%) ≥ 2
none were 0
Median no. = 1
21 (22.6%) w/AFP>400
1(1.1%)w/ln(AFP)=0
Median n(AFP)=2.1
Range 22-40
12(12.9%)w/MELD=deMELD
13(14%) w/MELD =MELD EQ

60 (75%) >1cm
16(20%) were 0
Median size =2.3 cm
12 (15%) ≥ 2
none were 0
Median no. = 1
14 (17.5%) w/AFP>400
none w/ln(AFP)=0
Median ln(AFP)=3
Range 20-35
20(25%)w/MELD =deMELD
12(15%) w/MELD=MELD EQ

383 (79.8%) >1cm
88(18.3%) were 0
Median size = 2 cm
134 (27.9%) ≥ 2
none were 0
Median no. = 1
54 (11.3%) w/AFP>400 3
(<1%) w/ln(AFP)=0
Median ln(AFP)=2.6
Range 16-30
97(20.2%)w/MELD=deMELD
73(15.2%)w/MELD=MELD EQ

Comparison
Covariate
Waitlist time
+6.85 to MELD EQ if≥6 mo
Max tumor size
+21.2 to deMELD if>1cm
+1.194*size to MELD EQ
Number of tumors
+5.9 to deMELD if ≥ 2
+1.438*no. to MELD EQ
AFP or ln(AFP)
+5.9 to deMELD if >400
+1.324*ln(AFP) to MELD EQ
Lab MELD
+1.9*MELD to deMELD
+1.143*MELD to MELD EQ

MELD EQ and deMELD=22-24
n = 383 obs.
272 (71%) ≥6 mo

MELD EQ and deMELD=19-21
n = 1168 obs.
391(33.5%) ≥6 mo

176 (46%) >1cm
186(48.6%) were 0
Median size = 0.8 cm
96 (25.1%) ≥ 2
none were 0
Median no. = 1
11 (2.9%) w/AFP>400
14 (3.7%) w/ln(AFP)=0
Median ln(AFP)=1.8
Range 14-24
207(54%)w/MELD=deMELD
178(46.5%)w/MELD=MELD EQ

790(67.6%)>1 cm
342(29.4%)) were 0
Median size = 2 cm
109(9.3%)≥ 2
20(1.7%) were 0
Median no. = 1
35(3%) w/AFP>400
35(3%) w/ln(AFP)=0
Median ln(AFP)=1.6
Range 13-21
378(32.4%) w/MELD= deMELD
890(76.2%) w/MELD = MELD EQ

Table 7. Effect of covariates with score agreement.
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Comparison
Covariate
Waitlist time
+6.85 to MELD EQ if≥6 mo
Max tumor size
+21.2 to deMELD if>1cm
+1.194*size to MELD EQ
Number of tumors
+5.9 to deMELD if ≥ 2
+1.438*no. to MELD EQ
AFP or ln(AFP)
+5.9 to deMELD if >400
+1.324*ln(AFP) to MELD EQ
Lab MELD
+1.9*MELD to deMELD
+1.143*MELD to MELD EQ

Comparison

Waitlist time
+6.85 to MELD EQ if≥6 mo
Max tumor size
+21.2 to deMELD if>1cm
+1.194*size to MELD EQ
Number of tumors
+5.9 to deMELD if ≥ 2
+1.438*no. to MELD EQ
AFP or ln(AFP)
+5.9 to deMELD if >400
+1.324*ln(AFP) to MELD EQ
Lab MELD
+1.9*MELD to deMELD
+1.143*MELD to MELD EQ
Covariate

Comparison

Waitlist time
+6.85 to MELD EQ if≥6 mo
Max tumor size
+21.2 to deMELD if>1cm
+1.194*size to MELD EQ
Number of tumors
+5.9 to deMELD if ≥ 2
+1.438*no. to MELD EQ
AFP or ln(AFP)
+5.9 to deMELD if >400
+1.324*ln(AFP) to MELD EQ
Lab MELD
+1.9*MELD to deMELD
+1.143*MELD to MELD EQ

MELD EQ =31-35,deMELD=36-40
n = 147 obs.

MELD EQ =25-30, deMELD=36-40
n = 171 obs.

MELDEQ=25-30,deMELD=31-35
n = 285 obs.

109(74%)≥6 mo

9 (5.3%)≥6 mo

130 (45.6%)≥6 mo

147(100%) >1 cm
None were 0
Median size=2 cm
61(41.5%)≥ 2
None were 0
Median no. = 1
9(6.1%) w/AFP>400
15(10.2%) w/ln(AFP)=0
Median ln(AFP)=1.8
Range 22-35
0 w/MELD = deMELD
29(19.7%) w/MELD=MELD EQ

171(100%) >1cm
None were 0
Median size = 2.1 cm
109 (63.7%) ≥ 2
2 (1.2%) were 0
Median no. = 2
3 (1.8%) w/AFP>400
6 (3.5%) w/ln(AFP)=0
Median ln(AFP)=2.2
Range 22-30
0 w/MELD = deMELD
153 (89.5%) w/MELD=MELD EQ

285(100%) >1cm
None were 0
Median size = 2.2 cm
102 (35.8%) ≥ 2
None were 0
Median no. = 1
22(7.7%) w/AFP>400
20 (7%) w/ln(AFP)=0
Median ln(AFP)=2.3
Range 20-27
0 w/MELD = deMELD
109(38.2%) w/MELD=MELD EQ

MELDEQ=22-24,deMELD=25-30
n = 530 obs.

MELDEQ=16-18, deMELD=22-24
n = 390 obs.

MELD EQ =19-21,deMELD=16-18
n = 747 obs.

120 (22.6%)≥6 mo

14(3.6%) ≥ 6 mo

705 (94.4%)≥6 mo

530(100%) >1cm
None were 0
Median size = 2.4 cm
91 (17.2%) ≥ 2
1 (0.2%) was 0
Median no. = 1
22 (4.2%) w/AFP>400
33 (6.2%) w/ln(AFP)=0
Median ln(AFP)=1.6
Range 16-24
0 w/MELD = deMELD
347(65.5%)w/MELD=MELD EQ

390(100%) >1cm
None were 0
Median size = 2 cm
382(97.9%)≥ 2
None were 0
Median no. = 2
19(4.9%)w/AFP>400
6(1.5%) w/ln(AFP)=0
Median ln(AFP)=2.1
Range 14-18
0 w/MELD = deMELD
345(88.5%)w/MELD=MELD EQ

682(91.3%) >1cm
61 (8.2%) were 0
Median size = 2.2 cm
154 (20.6%) ≥ 2
8 (1.1%) were 0
Median no. = 1
22 (2.9%) w/AFP>400
11 (1.5%) /ln(AFP)=0
Median ln(AFP)=2.6
Range 11-18
585(78.3%) w/MELD=deMELD
0 w/MELD=MELD EQ

Table 8. Effect of covariates without score agreement.
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Covariate

Post-Transplant Survival
Post-transplant survival was compared for alternative MELD scores in
ranges 6-15, 16-21, 22-30, and 31-40; see Figure 10. A significant difference
was seen between the lowest risk group and the 22-30 group under both scores
(p=0.007, MELD EQ ; p=0.015, deMELD; see Table 9). For the MELD EQ , this 2230 group has a steady decrease in survival rate for about two years and then
nearly levels off, while for the deMELD this group has a slightly more gradual
decrease over time. The highest risk group had a higher survival rate for the first
year and then decreased quickly, while the highest risk group for deMELD had a
sharper decrease in the first 1 ½ months and then decreased gradually over
time. Data in this highest risk group were sparse under both scores as seen in
the numbers at risk.
Cox proportional hazard models were also fit to predict post-transplant
survival by these risk strata. The hazard ratio (HR) for the MELD EQ 22-30 group
was 1.588 (1.132, 2.228, p=0.007), and 1.477 (1.078, 2.022, p=0.015) for
deMELD 22-30 group, relative to the 6-15 groups. The HR’s were not significant
among the other strata as shown in Table 9, and proportional hazards
assumptions were met (global chi-squared 5.669, 3 df, p=0.129 for MELD EQ ;
global chi-squared 3.7, 3 df, p=0.296 for deMELD) 28.
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Figure 10. Post-transplant survival for HCC patients stratified by MELD EQ
and deMELD ranges. Kaplan-Meier survival curves for HCC patients with the
indicated alternative MELD score ranges at last follow up prior to transplant. The
number at risk in each stratum is shown for 0, 1, 2, and 3 years at the bottom of
each panel.

Group
<16
16-21
22-30
31-40

Group
<16
16-21
22-30
31-40

HR
reference
1.141
1.588
1.175

MELD EQ
95% CI
reference
0.937, 1.389
1.132, 2.228
0.293, 4.712

p-value
reference
0.189
0.007
0.820

HR
reference
1.052
1.477
1.386

deMELD
95% CI
reference
0.839, 1.320
1.078, 2.022
0.690, 2.787

p-value
reference
0.661
0.015
0.359

Table 9. Hazard Ratios for Post-Transplant Survival from Cox Proportional
Hazard Models
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DISCUSSION
Previous research has demonstrated that scheduled progression of
exception points is not an equitable method of prioritizing liver transplant
between HCC and non-HCC patients. While the current allocation scheme
implementing a six-month delay prior to granting exception points should improve
equity of outcomes, reverting to scheduled exception point progression may still
advantage HCC patients after six months and treats all HCC patients as having
the same dropout risk regardless of tumor characteristics or laboratory MELD as
discussed in Chapter 2. Hence it is unknown whether the current six-month
delay provides the final solution for equitable transplant for HCC and non-HCC
patients, and in the interim it is instructive to evaluate potential candidates for
equivalent MELD scores to assess their strengths and weaknesses. The
MELD EQ and deMELD models both show improvement over scheduled
progression of exception points, with better stratification of dropout and
transplant probabilities. Overall numerical comparisons of the two scores slightly
favored the MELD EQ for dropout prediction, with C-indices of 0.678 and 0.664
respectively. However, this result was not statistically significant as 95% CIs for
both C-indices overlapped. Both scores match actual dropout probabilities
comparably to laboratory MELD for non-HCC patients fairly well for patients with
alternative MELD scores <22, though the deMELD remains more closely aligned
for a longer time period than the MELD EQ (approximately 8 months vs 6 months)
once a patient enters a given score range. Neither score matches actual dropout
accurately for the higher risk groups with the exception of the MELD EQ for those
with scores 22-24.
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Differences in projected HCC dropout and non-HCC dropout were similar
overall between the MELD EQ and the deMELD. However, the projected dropout
tended to be closer to non-HCC dropout under the deMELD for equivalent scores
<22 and closer under the MELD EQ for equivalent scores ≥22.
A problem for both scores is that dropout would increase beyond nonHCC levels for groups with equivalent scores <16 if prioritization were based on
them. However, the average difference over one year between projected
dropout for these groups and actual dropout of analogous non-HCC groups is
around 0.01 – near zero in the first few months since entering a given risk strata
but increasing over time.
In contrast to the <16 groups, dropout is projected to decrease for higher
risk groups, especially under the deMELD. This is because actual transplant and
dropout probabilities for the higher risk groups are largely lower than those for
corresponding non-HCC risk groups, so transplanting them at a higher rate to
match non-HCC rates would be expected to decrease their dropout further.
In the original paper describing the MELD EQ

15

, actual dropout and

transplant probabilities were depicted similarly to Figures 6a, 6c, 7a and 7c in
this writing. These probabilities appear to have decreased in the newer data. A
possible explanation may be that people are able to wait longer than they could
in the past for transplant without dropping out, perhaps due to improvement in
other therapies or patient management. Both scores can indirectly account for
effects from other therapies (for example, ablation) if they are reassessed over
time, since if a patient receives ablation and their maximum tumor size is
reduced, their MELD EQ and deMELD scores would also be reduced accordingly.
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This consideration was also discussed in the paper describing the deMELD 13.
Under the scheduled exception point progression, which resumes after six
months with the recently implemented six-month delay, such a patient would
receive the same number of exception points at each three-month interval as a
patient who did not have another therapy (or any HCC patient who remained
eligible for exception points). However, as ablation and other treatments are not
covariates in either of the models evaluated, we did not directly look at their
effects in this study.
Both scores improve risk stratification and allow for more equitable
transplant probabilities. Although they do not match non-HCC transplant
probabilities perfectly, they are much closer than under scheduled exception
point progression for most risk groups. One notable difference between the two
scores is that the deMELD identifies more patients in higher risk (≥22) categories
at listing. The main reasons for this are 1) the MELD EQ assigns 6.85 more points
after six months on the list and 2) the deMELD gives much greater weight to
tumor size (21.2 points for tumors >1cm vs. 1.194 points for each cm for the
MELD EQ ). The deMELD also uses discrete cutoff points for most of the HCC
covariates while the MELD EQ uses continuous values. Thus, the deMELD may
be more “stable” compared to the MELD EQ for higher risk groups, in that a
change in score requires a larger change in the covariates than it would for the
MELD EQ .
Projected transplant under the deMELD matches non-HCC probabilities
well for these higher risk groups. However, a potential concern with prioritizing
higher risk HCC patients is earlier transplantation of patients with more
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aggressive tumors who may have poorer outcomes post-transplant. We did find
that post-transplant survival is significantly lower for the 22-30 equivalent MELD
score group compared to the lowest risk group for both scores, but no significant
differences were found between the other risk groups. Adjustment of both scores
may be warranted to avoid transplanting those at high risk for recurrence. This
concern was mentioned in the original publication of the deMELD as well, and
they suggested the possibility of using a 3-6 month waiting time along with their
score 13. Potential causes of lower post-transplant survival in the 22-30 group
(e.g. recurrence vs. graft failure or other causes) were not investigated in this
study. In addition, HCC dropout is already lower than that for non-HCC patients
for groups with scores ≥22, except for MELD EQ >35 after about 7 months from
reaching this score. The lower dropout probabilities for scores in this range
suggest that perhaps lower equivalent MELD scores could be more appropriate
for some patients in this group. A possible area for future research could be
simply modeling dropout of HCC and non-HCC patients based on laboratory
MELD alone, and equating dropout hazards or probabilities to determine an
appropriate adjustment to the MELD score for HCC patients.
One limitation of this study is that total risks/benefits between dropout,
transplant, and post-transplant survival were not considered. Other investigators
have discussed this 16,19,20, and overall utility (combined dropout/post-transplant
survival) is included in the model by Vitale et al14. Comparing that approach with
those studied in this paper is another potential area for future research.
However, the evaluation criteria for comparing the Vitale et al. score with the
MELD EQ /deMELD is difficult to determine given the differences in objectives
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between the studies. The covariates included in the models studied here have
also been studied as prognostic indicators for post-transplant outcomes,
particularly AFP 4,19,29. Another limitation of the current study is that while setting
time zero as the first time a patient enters a given risk category may be of greater
clinical interest, it does not allow for projections for non-HCC patients under the
proposed scoring schemes. However, comparison to actual non-HCC outcomes
is useful for assessing how well the equivalent scores would improve equity
between non-HCC and HCC transplant and dropout rates.
A strong point of this study is that although several models incorporating
HCC characteristics for transplant prioritization have been proposed, no previous
studies were identified that compared projected outcomes between two proposed
HCC-specific models as well as with actual practice. While the current results do
not provide a clear-cut answer to which of these scores better prioritizes HCC
patients, they do highlight strengths and weaknesses of each which can provide
direction for ongoing work on an HCC prioritization score.
In summary, the MELD EQ and deMELD would both improve equity in
transplant access between HCC and non-HCC patients compared to scheduled
progression. While overall matching of projected dropout probabilities with nonHCC levels is nearly identical between the two scores, the deMELD does a better
job of matching the lower risk scores ≤21. An advantage of the MELD EQ is that it
“builds in” additional points at six months waitlist time and thus is a natural
counterpart to the current six-month delay in granting exception points. For the
deMELD, an advantage is that projected transplant probabilities are relatively
close to those of non-HCC patients in most analogous MELD score ranges.
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Also, since the deMELD uses discrete cutoff points for most of the HCC
covariates the score is unlikely to change dramatically over time. Disadvantages
of both scores include projected dropout probabilities that exceed non-HCC
probabilities for those with alternative MELD scores <16, and potential for
prioritizing higher risk patients with poorer post-transplant survival and lower
actual dropout rates. Thus further calibration and development of both scores is
recommended before their implementation.
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CHAPTER 4
SUMMARY
Improvement in prioritization of liver transplant for patients with HCC is
needed, as scheduled progression of exception points does not consider tumor
characteristics and treats all HCC patients similarly regardless of their dropout
risk. The possible solutions evaluated here do offer improvement, but each has
limitations.
While the newly implemented six-month delay in assigning exception
points to HCC patients will help address the disparity in transplant rates between
HCC and non-HCC patients, the improvement will mostly be seen for the first six
months as discussed in Chapter 2. After this time, transplant probabilities for
HCC patients will quickly return to exceeding those for non-HCC patients and
also become similar among HCC dropout risk strata.
The MELD EQ would help equalize dropout probabilities between HCC and
non-HCC patients over time, but would reduce transplant probabilities for HCC
patients below those of non-HCC patients. Use of the MELD EQ beginning at six
months on the waiting list is projected to match non-HCC transplant probabilities
well with very good risk stratification but may increase HCC dropout, especially
for the highest risk group.
Comparison of the MELD EQ and the deMELD scores, as shown in Chapter
3, again revealed that both scores show promise but are projected to increase
dropout probabilities beyond those of non-HCC patients in the same ranges for
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patients with equivalent scores <16. However, patients in this group currently
have low dropout risk, and the projected increase above non-HCC dropout
probabilities is not large for either score. For the higher risk groups (equivalent
scores of at least 22), both scores would make transplant probabilities more
equitable with non-HCC patients but then decrease dropout below that of nonHCC patients in the same risk groups, particularly for the deMELD. The deMELD
assigns points heavily for tumor size, so a possible disadvantage is that patients
scored higher by deMELD could be at risk for post-transplant recurrence. This
study did find that patients in some high-risk groups may have worse posttransplant survival. This is also discussed in the original paper for the deMELD
and the authors suggest possibly using a waiting period before use of the
score13. The MELD EQ assigns more points for waitlist time of at least six months,
but does not weight tumor size as heavily. Thus either score may have potential
for use in conjunction with the six-month delay or after six months waitlist time.
Alternatively, perhaps after further calibration, a score such as the deMELD or
the MELD EQ could replace the scheduled progression altogether. Further
evaluation and research of these scores and other alternative prioritization
schemes could aid in such calibration and refinement.
The methods of evaluating these prioritization schemes in the preceding
chapters had several strengths and weaknesses. Somewhat different projection
methods were used to evaluate the six-month delay and to compare the two
equivalent MELD scores. Because relatively few patients are classified in the
higher risk categories at listing, taking time zero as time a patient first enters a
risk category, as described in Chapter 3, was more appropriate for comparing the
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two equivalent MELD scores. A limitation of using time first entering a risk state
as time zero is that interpretation and comparison among risk groups may be
less straightforward. Also, the projection method to include effects on non-HCC
patients was not employed in the comparison study since it uses total number of
organs transplanted at a given time and the proportions going to each stratum of
HCC and non-HCC patients at a given time. Thus, the projections for the
comparison in Chapter 3 only included those for HCC patients. One strength of
this approach is that it can be more relevant clinically to determine a patient’s
probability of dropout from the time they develop a certain set of values of the
relevant covariates.
For evaluating the six-month delay in Chapter 2, it was necessary to
define time zero as the initial waitlist time, since the delay of six months is
defined as time since listing. A limitation of using time since listing is that data
can be sparse in the higher risk categories as mentioned earlier, since relatively
few patients are classified in these higher risk groups at listing. An attempt to
account for this was made by combining the higher risk categories for the sixmonth delay/MELD EQ comparison. The projection method to include non-HCC
patients has limitations as mentioned earlier in that it does not reflect calendar
time for the whole group, so the estimates of available organs at each time may
not be completely realistic. However, since prioritization schemes were
compared using the same methods, it is still a useful comparison of the
schemes. Overall, a strength of both studies described here is that projections
were used to evaluate outcomes for HCC and non-HCC patients as whole
groups as well as among different risk strata under three different prioritization
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methods. Additionally, this study identified strengths and weakness of each
scheme that may help guide further research and improvement of the scores.
The MELD EQ and the deMELD were selected for comparison for this
project because they were derived most similarly, but evaluation of additional
scoring methods, such as the method by Vitale et al that includes a utility score14
could be an area for future research. Evaluation of such scores using a model
that considered both waitlist dropout and post-transplant mortality could be useful
for determining net benefit. Additionally, further calibration of a score similar to
the MELD EQ or deMELD could be attempted by using simulated data to equate
dropout and/or transplant outcomes between HCC and non-HCC patients.
Further, exploration of new covariates that could influence waitlist dropout and
post-transplant outcomes, such as other HCC-related biomarkers or response to
other therapies for HCC, could be beneficial. Alternatively, equating dropout risk
between HCC and non-HCC patients with MELD as the only covariate may help
determine an appropriate and simple adjustment to the laboratory MELD for HCC
patients.
In conclusion, transplant prioritization has not been equitable between
HCC and non-HCC patients. Potential improvement has been made with
implementing the six-month delay though it still may advantage HCC patients
after 6 months. Possible solutions have been studied and proposed through
alternative scoring schemes. While these improvements represent progress in
decreasing this disparity, more progress is needed and further research on HCCspecific prioritization methods could help address this need.
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